(lp0
S"Analyst's Indicator Review for 22nd Century Group, Inc. , ZIOPHARM ... The USA Commerce - 16 hours ago The share price is now up 3.59% for the past three months. Latest closing price was 5.41% above its 50-day moving average and -3.71% below its 200-day moving average.Earnings Clues on 22nd Century Group, Inc. , ZIOPHARM Oncology, Inc ... - StockNewsJournalZIOPHARM Oncology Inc.  Closes Lower On Volume Spike - StockNewsUnion"
p1
aS'ZIOPHARM Oncology Inc  Moves Lower on Volume Spike for March 21 Equities.com - Mar 21, 2017 ZIOPHARM Oncology Inc  traded on unusually high volume on Mar. 21, as the stock lost 5.93% to close at $5.87. On the day, ZIOPHARM Oncology Inc saw 2.04 million shares trade hands on 9,729 trades. Considering that the stock averages only a&nbsp;...What Are Analysts Report About ZIOPHARM Oncology, Inc.  - News Oracle'
p2
aS'Griffin Lifts Price Target on ZIOPHARM Oncology Inc.  Ahead of ... Smarter Analyst - Feb 9, 2017 Griffin analyst Keith Markey sees golden prospects ahead for ZIOPHARM Oncology Inc. , particularly taking into account the seven clinical trials the firm has forthcoming on the table for this year; trials which the analyst commends as&nbsp;...ZIOPHARM Oncology, Inc.  added about 7.4 percent in value since last ... - The Independent Republic'
p3
aS"Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics Motley Fool - Nov 3, 2016 And although it hasn't been as closely associated with CAR-T as Juno Therapeutics, Ziopharm Oncology  is part of a collection of entities  developing a therapeutic pipeline in the same class,&nbsp;...ZIOPHARM Announces Four Presentations at the 2016 ASH Annual Meeting - GlobeNewswire "
p4
aS"Company Update : ZIOPHARM Oncology Inc. Announces 4Q:16 Financial ... Smarter Analyst - Feb 16, 2017 ZIOPHARM Oncology Inc.  announced financial results for the fourth quarter ended December 31, 2016, and provided an update on the Company's recent activities.Ziopharm 4Q Loss 11 Cents a Share  - InvestopediaZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on ... - GlobeNewswire "
p5
aS"The Reason Behind ZIOPHARM Oncology Inc.'s 11% Gain Motley Fool - Nov 10, 2016 Shares of ZIOPHARM Oncology , a clinical-stage biopharmaceutical company focused on the development of various immunotherapeutic cancer treatments, surged as much as 11% during Thursday's trading session after the company&nbsp;...Stock Update : ZIOPHARM Oncology Inc. Reports Third Quarter 2016 ... - Smarter Analyst"
p6
aS'Griffin Commends ZIOPHARM Oncology Inc.  Following Suspension Of Breast ... Smarter Analyst - Feb 27, 2017 ZIOPHARM Oncology Inc.  has indicating the firm will be shifting its R&amp;D pipeline, centering its IL-12 gene therapy program on glioblastoma following the suspension of future development of its breast cancer therapy program.ZIOPHARM Oncology Inc  Rating Lowered to Sell at Zacks Investment Research - Sports Perspectives'
p7
aS'Company Update : ZIOPHARM Oncology Inc. And Intrexon Corp To ... Smarter Analyst - Jan 10, 2017 ZIOPHARM Oncology Inc.  and Intrexon Corp  announced the signing of a Cooperative Research and Development Agreement  with the National Cancer Institute  for the development of adoptive cell transfer&nbsp;...'
p8
aS"Better Buy: Ziopharm Oncology, Inc. vs. Intrexon Corporation Motley Fool - Oct 14, 2016 The close relationship between Ziopharm Oncology  and Intrexon  hasn't gone unnoticed by investors -- in fact, it's impossible to overlook since the latter is likely responsible for a majority of the former's $660 million market cap."
p9
aS'Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool - Sep 24, 2016 Clinical-stage biotechs Ziopharm Oncology  and Alnylam Pharmaceuticals , for example, have both suffered in 2016.'
p10
a.